Wellesley, MA, United States of America

Florian Püehler


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Florian Püehler: Innovator in Pharmaceutical Chemistry

Introduction

Florian Püehler is a notable inventor based in Wellesley, MA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of kinase inhibitors. His work is characterized by a focus on innovative compounds that have the potential to address serious medical conditions.

Latest Patents

Florian Püehler holds 1 patent for his invention titled "Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors." This patent describes a range of substituted pyrrolopyrimidinylamino-benzothiazolone compounds, which are designed to be used in pharmaceutical compositions for the treatment or prophylaxis of hyper-proliferative and angiogenesis disorders. The invention includes methods for preparing these compounds and their use in combination with other active ingredients.

Career Highlights

Florian Püehler is associated with Bayer Pharma Aktiengesellschaft, a leading global pharmaceutical company. His role at Bayer has allowed him to contribute to cutting-edge research and development in the pharmaceutical industry. His expertise in medicinal chemistry has positioned him as a valuable asset in the quest for new therapeutic solutions.

Collaborations

Throughout his career, Florian has collaborated with esteemed colleagues, including Ulrich Klar and Lars Wortmann. These partnerships have fostered a collaborative environment that enhances innovation and drives forward the development of new pharmaceutical agents.

Conclusion

Florian Püehler's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions to the development of kinase inhibitors highlight the importance of research in addressing complex medical challenges. His ongoing efforts continue to inspire advancements in drug development and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…